Adverse Event Report Puts Safety of Durata Leads in Question
A report of an exposed conductor in a St. Jude defibrillator lead has renewed questions about the safety of some of the company’s cardiac products.
According to the report, filed in the FDA Manufacturer and User Device Experience (MAUDE) database with an incident date of April 18, a patient was injured after a conductor in a St. Jude Durata lead externalized, or was exposed through its insulation. The report was filed by a physician, but no other identifying information was included.
Durata leads were thought to be free of the design flaw that prompted St. Jude to recall roughly 227,000 Riata leads in 2011. At the time, the company acknowledged two patient deaths and one serious injury as a result of externalization.
Discover how the FDA measures the severity of a risk and take away the knowledge you need to create and administer a risk management file.
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!